Biorchestra specializes in innovative RNA therapeutics for neurodegenerative and other disorders. Our IV-formulated RNA medicines platform combines multiple modalities, chemistry innovations, and deep insights into human genetics to deliver scientific breakthroughs that treat rare and prevalent disorders. Our toolkit includes proprietary targeting ligands with an IV-formulated, non-lipid polymer and broad RNA cargo chemistry validation (ASO, siRNA, mRNA), providing premier capabilities for designing and delivering durable and potent drug candidates that optimally address disease biology through systemic administration. Our diverse pipeline includes late pre-clinical programs in Alzheimer's, ALS, and Parkinson's disease and earlier preclinical programs in Retina and Obesity.